TheTechno Optimist.

GalleriGRAIL—FDA Molecular and Clinical Genetics Advisory Committee endorses Galleri, recommending approval for multi-cancer early detectionGalleriGRAIL—PATHFINDER 2 trial results published in Nature Medicine, showing 6.5-fold increase in cancer detection with Galleri blood test

GRAIL

Galleri blood test, multi-cancer early detection, liquid biopsy

USpublicest. 2015grail.com (opens grail.com)Checked 11 Oct

The brief

Analyst view
  • Galleri detects signals from 50+ cancer types using blood DNA methylation patterns.
  • NHS-Galleri (142,000+ UK) and PATHFINDER 2 (35,878 North America) are the largest MCED trials.
  • Galleri detection increased 6.5-fold vs. standard screening. FDA advisory recommended approval Sept 2026.

Technical approach

As reported
Methylation patterns

DNA methylation detects cancer

Circulating DNA in blood carries methylation patterns unique to cancer cells, distinguishable from healthy cell DNA.

Machine learning

Algorithm predicts cancer tissue origin

When cancer is detected, machine learning narrows tissue type to guide imaging and biopsy.

Breadth

One blood test for 50+ cancers

Screens simultaneously for many cancers (mammography only shows breast, colonoscopy only shows colon).

Primer